Just like UnitedHealth, this healthcare giant tumbles after financial shocker

Centene (NYSE: CNC) shares plummeted over 20% after the healthcare giant withdrew its full-year financial guidance and sharply lowered its 2025 earnings forecast from an expected $7.28 to approximately $2.75 per share, citing a $1.8 billion shortfall. This significant downgrade stems primarily from unexpectedly high Medicaid costs, particularly in behavioral health and expensive prescription drugs, coupled with a less favorable enrollee mix in ACA marketplace plans. The move echoes recent challenges faced by UnitedHealth Group (NYSE: UNH) and intensifies investor concerns over rising costs and mounting pressure across the broader health insurance sector.

Analysis

Centene's (CNC) stock plummeted by over 20% following the withdrawal of its full-year financial guidance and a drastic reduction in its 2025 earnings forecast. The company now anticipates earnings of approximately $2.75 per share, a significant miss from the Wall Street consensus of $7.28, attributing the revision to a $1.8 billion shortfall. This downgrade is driven by unexpectedly high Medicaid costs, specifically in behavioral health and expensive prescription drugs, as well as a less favorable enrollee mix in its ACA marketplace plans which has negatively impacted risk-adjustment payments. Management's warning that further revisions may be necessary as more claims data becomes available introduces significant forward-looking uncertainty. While the company cited strong performance in its Medicare Advantage business and disciplined SG&A expenses, these factors were insufficient to offset the negative sentiment. The situation closely mirrors recent turmoil at UnitedHealth Group (UNH), which also withdrew its 2025 outlook due to surging costs, indicating a broader, sector-wide issue of rising cost pressures and poor earnings visibility within the health insurance industry.

Key Decisions for Investors

• Given the severity of the earnings cut and management's admission of poor visibility into cost trends, investors should exercise extreme caution with Centene, as the stock is likely to remain highly volatile until there is concrete evidence of cost stabilization.
• The parallel guidance withdrawals at both Centene and UnitedHealth highlight a systemic, sector-wide headwind from rising healthcare costs, warranting a portfolio review to assess exposure to margin compression risk across the entire managed care industry.
• Investors should closely monitor upcoming quarterly reports and claims data not just from Centene but from its peers for any changes in utilization trends, particularly in Medicaid and Medicare Advantage, as this will be the key indicator for a potential sector recovery.
• The market's complete dismissal of positive news regarding Medicare Advantage performance and SG&A discipline suggests that for the near term, Centene's valuation will be exclusively driven by its ability to control costs in its government-sponsored plans.